Document is current
Any future updates will be listed below
-
Authors
Willmann, Matthias http://orcid.org/0000-0003-0095-4640
Vehreschild, Maria J. G. T.
Biehl, Lena M.
Vogel, Wichard
Dörfel, Daniela
Hamprecht, Axel
Seifert, Harald
Autenrieth, Ingo B.
Peter, Silke
-
Funding
Funding for this research was provided by:
German Center for Infection Research (TTU 08.802)
- License Information
-
More Information
Article History
Received: 20 May 2019
Accepted: 27 August 2019
First Online: 18 September 2019
Ethics approval and consent to participate
: The local ethics committees approved the study (reference numbers: 661/2013BO1 and 14-021, respectively). All patients provided written consent before participating in the study. Data monitoring of patient data was performed at both centers. The study has been registered at ExternalRef removed with the identifier NCT02058888.
: Not applicable.
: MJGTV is a consultant to Alb Fils Kliniken GmbH, Berlin Chemie, MSD/Merck, and Astellas Pharma; has served at the speakers’ bureau of Astellas Pharma, Basilea, Gilead Sciences, Merck/MSD, Organobalance, and Pfizer; received research funding from 3M, Astellas Pharma, DaVolterra, Gilead Sciences, Merck/MSD, Morphochem, Organobalance, and Seres Therapeutics.The other authors declare that they have no competing interests.
